Cancer Aware · Patient & Family Guide

Immunotherapy in Endometrial Cancer

Immune checkpoint inhibitors help the immune system recognize and attack cancer. They have changed treatment for advanced endometrial cancer, especially mismatch repair deficient disease.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 17 of 25

What you will learn

  • Distinguish first-line combinations from later-line single-agent treatment.
  • Understand RUBY and NRG-GY018 without confusing PFS and survival.
  • Recognize immune-related adverse effects and evidence limits.

Who may benefit?

MMRd/MSI-H cancers are particularly sensitive to checkpoint inhibition, but responses are not guaranteed. Benefit from chemotherapy–immunotherapy combinations also occurs in MMR-proficient disease, with a different magnitude and evidence profile. PD-L1 CPS positivity is not generally required for the main endometrial indications described here.

In the United States, pembrolizumab and dostarlimab are each approved with carboplatin/paclitaxel followed by maintenance immunotherapy for primary advanced or recurrent endometrial cancer regardless of MMR status. Durvalumab with chemotherapy followed by durvalumab has a US indication restricted to dMMR disease. These are distinct regimens, not medicines to combine with one another.

Landmark evidence

StudyPopulation and comparisonMain evidence and limit
RUBY494 patients with eligible primary advanced or first recurrent cancer; dostarlimab plus chemotherapy then maintenance versus placebo regimen2024 overall-survival analysis HR 0.69 overall; larger effect in dMMR/MSI-H. pMMR subgroup uncertainty should not be hidden
NRG-GY018 / KEYNOTE-868Measurable stage III/IVA or stage IVB/recurrent disease; carcinosarcoma excluded; separate dMMR and pMMR cohorts; pembrolizumab regimen versus placeboStrong PFS improvement in both cohorts; FDA analysis HR 0.30 dMMR and 0.60 pMMR
GARNETSingle-arm dostarlimab in previously treated dMMR advanced/recurrent diseaseResponse evidence supported later-line approval; not a randomized survival comparison

PFS means time without progression or death; overall survival measures survival from trial entry. A hazard ratio describes relative event rates over follow-up, not an individual's chance of cure. RUBY's 2024 pMMR overall-survival estimate had a confidence interval crossing 1, despite a favourable trend. It should not be presented as a definitive subgroup survival result.

NRG-GY018 allowed prior adjuvant chemotherapy with a sufficient treatment-free interval; its measurable-disease requirements differed by stage. Trial eligibility should not be substituted for the wording of a current regulatory label.

The NRG group's 2026 conference update reported sustained numerical overall-survival benefit, with a statistically uncertain pMMR comparison and substantial subsequent immunotherapy use in control patients. This newer update should be distinguished from the original peer-reviewed PFS evidence and not treated as a precise prediction for an individual.

DUO-E: a distinct three-arm study

DUO-E randomized 718 patients with newly diagnosed advanced or recurrent endometrial cancer to chemotherapy with placebo, chemotherapy with durvalumab followed by durvalumab, or chemotherapy with durvalumab followed by durvalumab plus olaparib. The 2024 primary report found PFS hazard ratios of 0.71 and 0.55 respectively versus control in the overall population. MMR subgroup findings were exploratory, and overall survival was immature at that analysis. The study does not establish that olaparib should be added to every checkpoint regimen. Its results led to different US and European indications, described below.

Treatment after progression and regional differences

Single-agent dostarlimab has a US indication for dMMR advanced/recurrent endometrial cancer after platinum when curative surgery or radiation is not an option. Pembrolizumab also has relevant MSI-H/dMMR indications in eligible previously treated disease. These data largely concern patients without previous checkpoint inhibition. Simply switching one PD-1 medicine for another after resistance is not an established universal strategy.

European durvalumab approval differs from the US: after initial chemotherapy–durvalumab, maintenance is durvalumab alone for dMMR and durvalumab–olaparib for pMMR disease. Local labels, access and reimbursement must be checked. Approval for advanced disease does not automatically establish routine use after surgery for every early-stage cancer.

Safety and treatment duration

Immune effects can inflame lungs, bowel, liver, kidneys, skin, nerves or hormone glands. New diarrhoea, cough, breathlessness, severe fatigue, headache, weakness or excessive thirst should be reported promptly. Effects can occur after treatment stops. Severe symptoms need urgent assessment; management may require holding treatment and immunosuppression under specialist care.

Autoimmune disease, organ transplantation and chronic immunosuppression require individualized assessment. Treatment duration follows the regimen and local label, with stopping for progression or unacceptable toxicity; pivotal maintenance schedules are not identical. Longer treatment is not automatically better.

Questions and take-home messages

Ask which disease setting and biomarker support the recommendation, whether you previously received immunotherapy, how long treatment is planned and whom to call for symptoms. Carry an immunotherapy alert card if provided. Do not dismiss a new symptom as ordinary chemotherapy toxicity without contacting the team.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy